- Meeting abstract
Blood substitutes consumption and coagulation changes: 200/0.5 vs 130/0.4 hydroxyethyl starch administration
Critical Care volume 7, Article number: P109 (2003)
The aim of the study was to evaluate blood substitutes consumption and coagulation profile differences in patients undergoing liver transplantation (LT) receiving volume replacement with 6% hydroxyethyl starch (HES 200/0.5) or with a low-molecular weight (LMW) HES (130/0.4) .
Thirty-five consecutive patients scheduled for LT were prospectively randomized to receive either 6% HES (group HES; n = 20) or LMW (group LMW; n = 15) for additional volume replacement. Normal saline at 10 ml/kg per hour was continuously infused in all patients. Conventional global coagulation tests, hemoglobin, hematocrit and platelet values were monitored at the start of surgery (T0), during the anhepatic phase (T1), and at the end of surgery (T2). All data yielded were compared and analyzed with the paired Student t test: P < 0.05 was considered significant (SPSS, PC plus).
No differences in coagulation profile was observed between groups. Fluid and blood substitutes consumption are reported in Table 1.
We observed the same coagulation profile and minor blood components consumption using either HES or LMW, and they can be both safely used in liver transplant patients.
Bennett-Guerrero E, et al.: Arch Surg 2001, 136: 1177-1183. 10.1001/archsurg.136.10.1177
About this article
Cite this article
Costa, M., Pompei, L., Coccia, C. et al. Blood substitutes consumption and coagulation changes: 200/0.5 vs 130/0.4 hydroxyethyl starch administration. Crit Care 7, P109 (2003). https://doi.org/10.1186/cc1998
- Blood Component
- Hydroxyethyl Starch
- Coagulation Test
- Volume Replacement
- Undergo Liver Transplantation